Home / Health / NHS Trials Psychedelic Therapy for Severe Depression
NHS Trials Psychedelic Therapy for Severe Depression
6 Jul
Summary
- Psilocybin, a compound from magic mushrooms, is being trialed for severe depression.
- An NHS hospital in Doncaster is part of a groundbreaking psilocybin treatment trial.
- Researchers hope psilocybin will offer a new, effective treatment for mental health.
In a significant development for mental healthcare, an NHS hospital is now participating in a trial using psilocybin, the psychedelic compound found in magic mushrooms. This research aims to explore its potential as a treatment for severe depression, particularly for individuals with treatment-resistant conditions.
Leonie Schneider, who experienced treatment-resistant depression for over 24 years, found profound healing through a psilocybin trial at Imperial College London in 2019. She reported regaining a sense of agency and has not needed antidepressants since.
Clerkenwell Health has established an NHS-embedded research site in Doncaster, South Yorkshire, to facilitate these trials. This initiative, developed with Rotherham Doncaster and South Humber NHS Foundation Trust (RDaSH), aims to provide NHS patients with earlier access to investigational treatments. The goal is to create a model for delivering such mental health trials within the NHS framework.
Researchers hypothesize that psilocybin enhances neuroplasticity, allowing the brain to restructure thought patterns. Mehul Vaghani from Clerkenwell Health likens this to creating new neural pathways, helping individuals reframe challenging thoughts. Participants are administered psilocybin under constant supervision by therapists and nurses.
While the trials show promise, some experts urge caution. Professor Joanna Moncrieff points out a lack of long-term safety data and highlights the potential for amplified placebo effects in trials where blinding is difficult. Professor Oliver Howes emphasizes the need for more studies to assess psilocybin's performance in routine practice, alongside psychotherapy.
Despite these concerns, Professor David Nutt, who led the Imperial study, believes psilocybin is a powerful, often single-dose therapy for treatment-resistant depression, representing a major breakthrough due to its fundamentally different mechanism of action compared to other treatments. He advocates for its approval within the NHS, provided further large-scale, well-designed trials confirm its safety and efficacy.
